Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China
Ocean Biomedical (NASDAQ: OCEA) has received a patent grant from the China National Intellectual Property Administration (CNIPA) for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance tumor cell destruction. The patent strengthens the company's intellectual property portfolio in one of the world's largest pharmaceutical markets.
The technology represents a potential breakthrough in cancer immunotherapy by simultaneously targeting CHI3L1, a key regulator of immune suppression, and PD1, an established immune checkpoint. This dual-targeting approach aims to overcome current limitations in cancer treatment by blocking two key pathways tumors use to suppress immune response, potentially leading to more effective and durable patient outcomes.
This grant extends Ocean Biomedical's patent protection beyond its existing coverage in the United States and Europe, supporting its global expansion strategy in cancer immunotherapy development.
Ocean Biomedical (NASDAQ: OCEA) ha ricevuto un brevetto dalla China National Intellectual Property Administration (CNIPA) per i suoi anticorpi bispecifici che mirano a CHI3L1 e PD1, progettati per migliorare la distruzione delle cellule tumorali. Questo brevetto rafforza il portafoglio di proprietà intellettuale dell'azienda in uno dei più grandi mercati farmaceutici del mondo.
La tecnologia rappresenta una potenziale svolta nell'immunoterapia contro il cancro, mirando simultaneamente a CHI3L1, un regolatore chiave della soppressione immunitaria, e a PD1, un checkpoint immunitario consolidato. Questo approccio a doppio bersaglio mira a superare le attuali limitazioni nel trattamento del cancro bloccando due percorsi chiave che i tumori utilizzano per sopprimere la risposta immunitaria, potenzialmente portando a risultati più efficaci e duraturi per i pazienti.
Questo brevetto estende la protezione brevettuale di Ocean Biomedical oltre la copertura esistente negli Stati Uniti e in Europa, sostenendo la sua strategia di espansione globale nello sviluppo dell'immunoterapia contro il cancro.
Ocean Biomedical (NASDAQ: OCEA) ha recibido una concesión de patente de la Administración Nacional de Propiedad Intelectual de China (CNIPA) para sus anticuerpos bispecíficos dirigidos a CHI3L1 y PD1, diseñados para mejorar la destrucción de células tumorales. La patente refuerza el portafolio de propiedad intelectual de la empresa en uno de los mercados farmacéuticos más grandes del mundo.
La tecnología representa un posible avance en la inmunoterapia contra el cáncer al atacar simultáneamente a CHI3L1, un regulador clave de la supresión inmunitaria, y a PD1, un punto de control inmunitario establecido. Este enfoque de doble objetivo busca superar las limitaciones actuales en el tratamiento del cáncer al bloquear dos vías clave que los tumores utilizan para suprimir la respuesta inmunitaria, lo que podría llevar a resultados más efectivos y duraderos para los pacientes.
Esta concesión extiende la protección de patentes de Ocean Biomedical más allá de su cobertura existente en Estados Unidos y Europa, apoyando su estrategia de expansión global en el desarrollo de inmunoterapia contra el cáncer.
오션 바이오메디컬 (NASDAQ: OCEA)는 중국 국가 지식 재산권 관리국(CNIPA)으로부터 CHI3L1과 PD1을 표적으로 하는 이중 특이성 항체에 대한 특허를 받았습니다. 이는 종양 세포 파괴를 강화하기 위해 설계되었습니다. 이 특허는 세계 최대 제약 시장 중 하나에서 회사의 지식 재산 포트폴리오를 강화합니다.
이 기술은 면역 억제를 조절하는 주요 요소인 CHI3L1과 기존의 면역 체크포인트인 PD1을 동시에 표적으로 하여 암 면역 요법에서의 잠재적인 혁신을 나타냅니다. 이 이중 표적 접근 방식은 종양이 면역 반응을 억제하는 데 사용하는 두 가지 주요 경로를 차단하여 현재의 암 치료 한계를 극복하고, 환자에게 더 효과적이고 지속적인 결과를 가져올 수 있도록 합니다.
이 특허는 오션 바이오메디컬의 특허 보호 범위를 미국과 유럽의 기존 범위를 넘어 확장하여 암 면역 요법 개발에 대한 글로벌 확장 전략을 지원합니다.
Ocean Biomedical (NASDAQ: OCEA) a reçu un brevet de l'Administration nationale de la propriété intellectuelle de Chine (CNIPA) pour ses anticorps bispécifiques ciblant CHI3L1 et PD1, conçus pour améliorer la destruction des cellules tumorales. Ce brevet renforce le portefeuille de propriété intellectuelle de l'entreprise dans l'un des plus grands marchés pharmaceutiques du monde.
La technologie représente une avancée potentielle dans l'immunothérapie contre le cancer en ciblant simultanément CHI3L1, un régulateur clé de la suppression immunitaire, et PD1, un point de contrôle immunitaire établi. Cette approche de double ciblage vise à surmonter les limitations actuelles du traitement du cancer en bloquant deux voies clés que les tumeurs utilisent pour supprimer la réponse immunitaire, ce qui pourrait conduire à des résultats plus efficaces et durables pour les patients.
Ce brevet étend la protection par brevet d'Ocean Biomedical au-delà de sa couverture existante aux États-Unis et en Europe, soutenant sa stratégie d'expansion mondiale dans le développement de l'immunothérapie contre le cancer.
Ocean Biomedical (NASDAQ: OCEA) hat von der China National Intellectual Property Administration (CNIPA) ein Patent für seine bispezifischen Antikörper erhalten, die auf CHI3L1 und PD1 abzielen und zur Verbesserung der Zerstörung von Tumorzellen entwickelt wurden. Das Patent stärkt das geistige Eigentum des Unternehmens in einem der größten Pharmamärkte der Welt.
Die Technologie stellt einen potenziellen Durchbruch in der Krebsimmuntherapie dar, indem sie gleichzeitig CHI3L1, einen wichtigen Regulator der Immununterdrückung, und PD1, einen etablierten Immun-Checkpoint, angreift. Dieser duale Zielansatz zielt darauf ab, die aktuellen Einschränkungen in der Krebsbehandlung zu überwinden, indem er zwei Schlüsselwege blockiert, die Tumoren zur Unterdrückung der Immunantwort nutzen, was potenziell zu effektiveren und nachhaltigeren Ergebnissen für die Patienten führen könnte.
Diese Genehmigung erweitert den Patentschutz von Ocean Biomedical über die bestehende Abdeckung in den Vereinigten Staaten und Europa hinaus und unterstützt die globale Expansionsstrategie des Unternehmens im Bereich der Krebsimmuntherapie.
- Patent grant secured in major pharmaceutical market (China)
- Technology targets two key cancer pathways simultaneously
- Expands global IP portfolio beyond US and Europe
- Technology still in early development phase
- No clinical trial data or efficacy results presented
- Commercialization timeline uncertain
Insights
The grant of patent rights in China for Ocean Biomedical's bispecific antibodies represents a significant strengthening of their intellectual property position in a crucial market. China, as the world's second-largest pharmaceutical market, offers substantial commercialization potential for novel cancer immunotherapies.
This patent specifically covers bispecific antibodies targeting the unique combination of CHI3L1 and PD1 - a dual-targeting approach that differentiates it from most single-target immunotherapies currently dominating the market. The scope of protection appears robust, covering both the novel design and therapeutic applications.
The strategic value extends beyond just China, as this grant complements Ocean's existing IP portfolio in the US and Europe, creating comprehensive global protection. This three-market coverage (US/EU/China) is the gold standard for biopharma IP strategy, potentially making their technology more attractive for licensing or partnership deals.
However, investors should note that while patent protection is valuable, Ocean Biomedical still faces the standard development timeline challenges of moving from pre-clinical to clinical studies. The patent itself doesn't accelerate regulatory approval, though it does protect market exclusivity once approved.
This patent grant enhances Ocean's negotiating position with potential Chinese partners, which could accelerate market entry through licensing deals that generate upfront payments and royalties without requiring direct investment in Chinese clinical trials and commercialization infrastructure.
Ocean Biomedical's bispecific antibody approach targeting CHI3L1 and PD1 addresses a fundamental challenge in cancer immunotherapy: tumor immune evasion. The scientific rationale is compelling because it simultaneously blocks two distinct immune suppression mechanisms.
PD1 inhibition is already validated through approved drugs like pembrolizumab and nivolumab, but cancer cells often develop resistance. The addition of CHI3L1 targeting is scientifically notable because CHI3L1 promotes tumor growth through alternative immune-suppressive pathways not addressed by current therapies.
This dual-targeting strategy could potentially overcome the 40-60% non-response rate seen with existing PD1/PD-L1 inhibitors. By blocking both pathways within a single molecule, the approach may also reduce the toxicity profiles compared to combination therapies while improving efficacy.
The technology represents a potential advance over existing bispecific platforms that typically target CD3 and a tumor antigen to redirect T cells. Instead, Ocean's approach aims to remove multiple immunosuppressive barriers simultaneously.
While the patent grant doesn't provide clinical validation, the approach aligns with the industry's growing recognition that addressing multiple immune checkpoints offers better potential for durable responses. The ultimate value will depend on forthcoming pre-clinical and clinical data demonstrating superior efficacy over existing monotherapies or combinations, but securing global IP protection now is a critical foundation for future development.
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells.
This newly issued patent will strengthen Ocean Biomedical’s intellectual property portfolio and provides protection in one of the world’s largest pharmaceutical markets. The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 and PD1, key targets implicated in immune evasion by tumor cells.
Ocean Biomedical’s bispecific antibody technology represents a potential paradigm shift in cancer immunotherapy. By simultaneously targeting CHI3L1—a key regulator of immune suppression—and PD1, a well-established immune checkpoint, this novel approach has the potential to reinvigorate the immune system’s ability to combat tumors more effectively than existing treatments alone. By blocking both pathways, these antibodies could enhance immune-mediated tumor cell destruction, leading to more durable responses and better outcomes for patients.
“We are excited to receive this patent grant in China, marking a significant milestone in our global expansion strategy,” said Chirinjeev Kathuria, Chairman of Ocean Biomedical. “This recognition by CNIPA underscores the novelty and therapeutic potential of our bispecific antibody platform. We believe this technology has the potential to reshape the landscape of cancer immunotherapy by providing more effective treatment options for patients.”
Current immunotherapies are often limited by tumor resistance and immune evasion mechanisms. Ocean Biomedical’s technology seeks to address these limitations by taking a multi-pronged approach, blocking two key pathways that tumors use to suppress the immune response. This could result in more robust and sustained tumor control, significantly improving survival rates for patients who currently have limited treatment options.
The grant of this patent follows Ocean Biomedical’s continued success in securing intellectual property protection across key markets, including the United States and Europe. The company remains committed to leveraging its robust patent estate to drive the development and commercialization of novel immunotherapies.
Ocean Biomedical plans to continue collaborating with leading researchers, biopharma partners, and regulatory agencies to strive to accelerate the translation of its discoveries into transformative therapies.
About Ocean Biomedical
Ocean Biomedical (NASDAQ: OCEA) is a biopharmaceutical company focused on discovering and developing innovative therapies for cancer, infectious diseases, and fibrosis. By bridging world-class scientific discoveries with commercial development, the company aims to bring life-saving treatments to patients worldwide. For more information, visit www.oceanbiomedical.com.
Forward-Looking Statements
The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics and expectations. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this filing. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Ocean Biomedical Investor Relations info@oceanbiomedical.com
Ocean Biomedical Media Relations connect@oceanbiomedical.com
Source: Ocean Biomedical, Inc.
FAQ
What is the significance of OCEA's new patent grant in China?
How does OCEA's bispecific antibody technology work in cancer treatment?
What advantages does OCEA's dual-targeting approach offer over existing cancer treatments?
What markets does Ocean Biomedical (OCEA) now have patent protection in?
What is the current development stage of OCEA's bispecific antibody technology?
